Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Increased by Nordea Investment Management AB

Key Points

• Nordea Investment Management AB increased its holdings in Ultragenyx Pharmaceutical by 59.8% during the second quarter, now owning approximately 0.06% of the company valued at $2.2 million.
• The company reported a quarterly EPS of ($1.17), surpassing analyst expectations, with revenue increasing 13.2% year-over-year to $166.5 million.
• Analysts generally maintain positive ratings, with an average target price of $82.27, indicating a strong market outlook for Ultragenyx Pharmaceutical.

Nordea Investment Management AB grew its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 59.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,176 shares of the biopharmaceutical company's stock after buying an additional 22,509 shares during the period. Nordea Investment Management AB owned about 0.06% of Ultragenyx Pharmaceutical worth $2,208,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 669 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter valued at about $57,000. Headlands Technologies LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $59,000. Finally, Covestor Ltd raised its stake in Ultragenyx Pharmaceutical by 86.8% during the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after acquiring an additional 795 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $33.14 on Thursday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $56.38. The firm has a market cap of $3.19 billion, a price-to-earnings ratio of -5.99 and a beta of 0.21. The business's 50-day simple moving average is $30.55 and its 200-day simple moving average is $32.91.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm's revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the business's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the transaction, the executive vice president owned 73,271 shares of the company's stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 7,942 shares of the firm's stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the sale, the chief financial officer owned 98,227 shares of the company's stock, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,456 shares of company stock worth $328,486 over the last three months. 5.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Canaccord Genuity Group reduced their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wells Fargo & Company began coverage on Ultragenyx Pharmaceutical in a research report on Monday. They issued an "overweight" rating and a $65.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus price target of $82.27.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.